logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. A controlled trial of immunotherapy for asthma in allergic children.

    Article - En anglais

    Background Injections of allergens are widely prescribed for patients with asthma, but little is known about the effectiveness of immunotherapy.

    Methods We conducted a double-blind, placebo-controlled trial of multiple-allergen immunotherapy in 121 allergic children with moderate-to-severe, perennial (year-round) asthma.

    The children, who required daily medication for their asthma, were randomly assigned to receive subcutaneous injections of either a mixture of up to seven aeroallergen extracts or a placebo.

    Maintenance injections were continued for 18 months or longer.

    Medications were adjusted every two to three weeks on the basis of peak flow rates and symptoms.

    The principal outcome was the daily medication score.

    Bronchial sensitivity to methacholine (the concentration provoking a 20 percent decrease in the forced expiratory volume in one second [PC20]) was measured twice yearly.

    Results The median medication score declined from 5.4 to 4.9 in the immunotherapy group (P<0.001) and from 5.2 to 5.0 in the placebo group (P<0.001), but there was no significant difference between the groups (P>0.6).

    The number of days on which oral corticosteroids were used was similar in the two groups.

    Partial or complete remission of asthma occurred in 31 percent of the immunotherapy group and in 28 percent of the placebo group (P>0.5).

    There was no difference between the groups in the use of medical care, symptoms, or peak flow rates. (...)

    Mots-clés Pascal : Asthme, Allergie, Traitement, Immunothérapie, Injection, Allergène, Efficacité traitement, Homme, Appareil respiratoire pathologie, Bronchopneumopathie obstructive, Immunopathologie

    Mots-clés Pascal anglais : Asthma, Allergy, Treatment, Immunotherapy, Injection, Allergen, Treatment efficiency, Human, Respiratory disease, Obstructive pulmonary disease, Immunopathology

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 97-0156673

    Code Inist : 002B06F. Création : 21/05/1997.